Neumora Therapeutics, Inc. · NASDAQ:NMRA

Neumora Therapeutics — Guggenheim Emerging Outlook: Biotech Summit 2026

15 slides from Neumora Therapeutics's conference presentation, Feb 11, 2026

  1. Slide 1: February 2026 Guggenheim Emerging Outlook: Biotech Summit

    February 2026 Guggenheim Emerging Outlook: Biotech Summit

  2. Slide 2: Important Disclosures

    Important Disclosures This presentation contains forward-looking statements about Neumora Therapeutics, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including statements related to: Neumora’s intention to redefine neuroscience drug development by brin

  3. Slide 3: NMRA-511 demonstrated unsurpassed efficacy in patients with AD agitation

    NMRA-511 demonstrated unsurpassed efficacy in patients with AD agitation NMRA-511 Phase 1b key takeaways Well tolerated, with potential for higher dosing CMAI effect size similar to Auvelity in total population Unsurpassed CMAI effect size in patients with elevated anxiety For illustrative purposes

  4. Slide 4: Study to evaluate the effects of NMRA-511 among healthy elderly and adults with agitation

    Study to evaluate the effects of NMRA-511 among healthy elderly and adults with agitation associated with dementia due to Alzheimer's disease *Safety Assessments include adverse events, clinical laboratory, vital signs, physical examination, 12-lead electocardiogram (ECG), Columbia-Suicide Severity

  5. Slide 5: Demographics and baseline characteristics

    Demographics and baseline characteristics 170% medication compliance required per protocol 22 placebo patients excluded based on rater change driving outlier data (>3 standard deviations from the mean) 3Defined as Rating Anxiety In Dementia (RAID) score ≥12 Total Population Pre-specified elevated an

  6. Slide 6: NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in patients with elevated anxiety

    NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in patients with elevated anxiety CMAI Total Score Change from Baseline (pre-specified elevated anxiety sub-population) Mean Change in CMAI Sub-Scores at Week 8 (pre-specified elevated anxiety sub-population) NMRA-511 Placebo

  7. Slide 7: NMRA-511 drove unsurpassed reductions in CGI-S agitation scores in patients with elevated anxiety

    NMRA-511 drove unsurpassed reductions in CGI-S agitation scores in patients with elevated anxiety at baseline CGI-S Agitation Change from Baseline (pre-specified elevated anxiety sub-population) NMRA-511 Placebo NMRA-511 n=16, placebo n=21 Nominal p-values: **p<0.05, *p<0.1 Week 6 Week 8 LSMD (SE) -

  8. Slide 8: Strong clinical effect demonstrated on NPI agitation/aggression domain in patients with elevated anxiety

    Strong clinical effect demonstrated on NPI agitation/aggression domain in patients with elevated anxiety at baseline NPI Agitation/Aggression (NPI-AA) Change from Baseline (pre-specified elevated anxiety sub-population) NMRA-511 Placebo NMRA-511 n=16, placebo n=21 Nominal p-values: **p<0.05, *p<0.1

  9. Slide 9: Favorable tolerability and safety profile demonstrated

    Favorable tolerability and safety profile demonstrated TEAEs were typically mild to moderate in severity Low treatment discontinuations due to TEAEs (2.5%) Opportunity to evaluate higher doses of NMRA-511 based on tolerability TEAEs Incidence (≥5% in either treatment group) Placebo n=40 NMRA-511 n=4

  10. Slide 10: NMRA-511 demonstrated consistent unsurpassed efficacy across measures

    NMRA-511 demonstrated consistent unsurpassed efficacy across measures For illustrative purposes only. NMRA-511 has not been studied in head-to-head trials against Auvelity or Rexulti, and there are differences in compounds, trial designs and other factors which must be considered. Data presented as

  11. Slide 11: Appendix

    Appendix @

  12. Slide 12: Significant opportunity for a product with a differentiated benefit/risk profile

    Significant opportunity for a product with a differentiated benefit/risk profile For illustrative purposes only. NMRA-511 has not been studied in head-to-head trials against Auvelity or Rexulti, and there are differences in compounds, trial designs and other factors which must be considered. 1Calcul

  13. Slide 13: Alzheimer's disease agitation represents large market opportunity with significant unmet need

    Alzheimer’s disease agitation represents large market opportunity with significant unmet need 1Alzheimer's Association. 2025 Alzheimer's Disease Facts and Figures. Alzheimer's Dementia 2025;21(5). 2Van der Mussele S, et al. Aging Ment Health 2015;19(3):247-257. 3Image from Alzheimer’s Society Alzhei

  14. Slide 14: NMRA-511 demonstrated clinically meaningful reduction in CMAI total score and CMAI aggression sub-score

    NMRA-511 demonstrated clinically meaningful reduction in CMAI total score and CMAI aggression sub-score NMRA-511 demonstrated a 15.7-point reduction in CMAI total score at Week 8 CMAI aggression sub-score results suggest improvement on clinically relevant symptoms of AD agitation CMAI Total Score Ch

  15. Slide 15: © Neumora

    © Neumora

Neumora Therapeutics — Guggenheim Emerging Outlook: Biotech Summit 2026 on 6ix